What are you searching for?

Sign in
Breaking News, Promotions & Moves

Pierre Fabre Appoints Adriana Herrera CEO of New U.S. Affiliate

Herrera will be responsible for creating from scratch the new structure of Pierre Fabre Pharmaceuticals Inc.

By: Kristin Brooks

Managing Editor, Contract Pharma

Pierre Fabre Laboratories has appointed Adriana Herrera to the position of Chief Executive Officer of Pierre Fabre Pharmaceuticals Inc., its new Medical Care affiliate in the U.S.
 
Reporting to Jean-Luc Lowinski, CEO of Pierre Fabre Medical Care Business Unit, Adriana Herrera will be responsible for creating from scratch the new structure of Pierre Fabre Pharmaceuticals Inc. In this leadership role, her top priority will be to implement Pierre Fabre Medical Care innovation strategy to establish and expand its U.S. pharmaceutical presence with a focus on precision oncology and rare diseases.

Adriana Herrera’s first concern will be the commercialization in the US market of the first allogeneic immunotherapy designed to treat adults and children aged 2 and over who, after receiving an organ or bone marrow transplant, develop Epstein-Barr virus-positive post-transplant lymphoproliferative disease, and whose rights have been acquired from ATARA biotherapeutics. This treatment is already marketed by Pierre Fabre Laboratories in Europe.
 
Pierre Fabre Laboratories strategic focus is on innovative solutions in precision oncology, including the treatment of specific molecular mutations in colorectal,
breast, lung, and melanoma cancers. 
 
“We welcome Adriana, whose expertise and experience will be essential in the set-up and development of our oncology and rare disease activities in the United States, the world’s largest oncology market. Adriana’s commitment to patients aligns with our values. Her leadership will drive our company forward as she spearheads our new-born U.S. organization at this pivotal phase of growth,” said Eric Ducournau, CEO of Pierre Fabre Laboratories.

Before joining the company, Adriana held leadership roles at Kite Pharma as US General Manager, and Eisai US as Senior Vice President. She also held previous roles of increasing responsibility in marketing, sales, and operations at Novartis Oncology, as well as Bristol Myers Squibb, where she started her career in the industry.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters